Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versuscis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trial
โ Scribed by Cristiana Sessa; Giorgio Bolis; Nicoletta Colombo; Maurizio D'Incalci; Bernadette Mermillod; Ivana Valente; Costantino Mangioni
- Publisher
- Springer
- Year
- 1985
- Tongue
- English
- Weight
- 659 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Fifty-one patients with ovarian cancer were tients with < 2 cm residual disease had sigentered in a randomised trial comparing treat-nificantly higher rate of complete remission rnent with cisplatin + adriamycin + cyclo-than those with > 2 crn residual disease. Carphosphamide (PAC) to cisplatin + 4'
As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF). Seventy-one percent of all patients were post-